Tarsus Pharmaceuticals (TARS) has the first and only approved treatment for Demodex Blepharitis, Xdemvy. The FDA approved Xdemvy for treatment of Demodex Blepharitis in July 2023. CEO of Tarsus Pharmaceuticals Bobby Azamian, MD, PhD joins Oliver Renick to discuss the biopharmaceutical company. The company focuses on novel therapies or ophthalmic conditions. Tune in to find out more about the stock market today.
Morning Trade Live
09 Jan 2024
SHARE